<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491179</url>
  </required_header>
  <id_info>
    <org_study_id>200703032M</org_study_id>
    <nct_id>NCT00491179</nct_id>
  </id_info>
  <brief_title>Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin</brief_title>
  <official_title>Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Who Fail Interferon Alfa or Pegylated Interferon Alfa Monotherapy - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health, Executive Yuan, R.O.C. (Taiwan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is common in dialysis patients. Interferon&#xD;
      (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in&#xD;
      immunocompetent patients. Two meta-analyses evaluating the efficacy and safety of&#xD;
      conventional IFN alfa monotherapy showed that the sustained virologic response (SVR) rates&#xD;
      were 37% and 33%, respectively; and the corresponding dropout rates were 17% and 29.6%,&#xD;
      respectively. The efficacy and safety of pegylated IFN alfa-2a and 2b in treating dialysis&#xD;
      patients showed conflicting results, with a more favorable outcome of patients treated with&#xD;
      pegylated IFN alfa-2a (135-180 μg/week: SVR 33-75%, well tolerated) than those treated with&#xD;
      pegylated IFN alfa-2b (0.5-1.0 μg/week: SVR 12.5%, poorly tolerated), Currently, IFN-based&#xD;
      therapy to treatment HCV infection should be initiated in dialysis stages, because the use of&#xD;
      IFN in RT patients harbors high risks of acute graft rejection,and have low response rates&#xD;
      under the concomitant use of immunosuppressive agents.&#xD;
&#xD;
      Ribavirin, which has been used in combination with IFN to treat chronic hepatitis C in the&#xD;
      general patients and achieve a higher SVR rate than IFN monotherapy, is considered&#xD;
      contraindicated in dialysis patients with chronic hepatitis C due to the risk of severe&#xD;
      hemolytic anemia. However, some pilot studies evaluating combined conventional IFN alfa plus&#xD;
      low dose ribavirin (170-300 mg/day) showed SVR rates of 17%-66% after 24-48 weeks of&#xD;
      treatment.In addition, a recent study including 6 patients with combination of pegylated IFN&#xD;
      alfa plus low dose ribavirin also showed a SVR rate of 50%.&#xD;
&#xD;
      Although dialysis patients have a higher SVR rate to conventional IFN or pegylated IFN&#xD;
      monotherapy than patients with normal renal function for HCV therapy. More than half of these&#xD;
      patients are relapsers or non-responders to IFN monotherapy. Retreatment of HCV-patients with&#xD;
      normal renal function by combined pegylated IFN alfa plus ribavirin who fail to response to&#xD;
      IFN monotherapy has achieved a SVR rate of 28%. Based on the long-term favorable outcome in&#xD;
      dialysis patients who eradicate HCV, the aim of the study is to evaluate the efficacy and&#xD;
      safety of retreatment by pegylated IFN alfa-2a plus low dose ribavirin in dialysis patients&#xD;
      who fail to achieve HCV eradication by conventional or pegylated IFN alfa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is common in dialysis patients, with the reported&#xD;
      prevalence varying from 3% to 80% worldwide.(1-3) Although these patients usually have mild&#xD;
      symptoms and moderate elevation of alanine transaminase levels, recent international&#xD;
      collaborative survey and prospective studies found that anti-HCV seropositivity and positive&#xD;
      HCV RNA were risk factors for mortality and hepatocellular carcinoma (HCC).(4-7) Furthermore,&#xD;
      progressive hepatic fibrosis, poor patient and graft survival were observer in dialysis&#xD;
      patients with HCV infection who undergo renal transplantation (RT), suggesting&#xD;
      immunosuppression following RT may worsen the course of hepatic fibrosis and renal graft&#xD;
      function.(8-13) These lines of evidence indicate that HCV infection in the dialysis&#xD;
      population is an important issue to be tackled.&#xD;
&#xD;
      Interferon (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in&#xD;
      immunocompetent patients. In dialysis patients, treatment with conventional or pegylated&#xD;
      interferon has also received much attention recently. Two meta-analyses evaluating the&#xD;
      efficacy and safety of conventional IFN alfa monotherapy showed that the sustained virologic&#xD;
      response (SVR) rates were 37% and 33%, respectively; and the corresponding dropout rates were&#xD;
      17% and 29.6%, respectively.(14,15) The efficacy and safety of pegylated IFN alfa-2a and 2b&#xD;
      in treating dialysis patients showed conflicting results, with a more favorable outcome of&#xD;
      patients treated with pegylated IFN alfa-2a (135-180 μg/week: SVR 33-75%, well tolerated)&#xD;
      than those treated with pegylated IFN alfa-2b (0.5-1.0 μg/week: SVR 12.5%, poorly&#xD;
      tolerated),(16-21) which may result from different pharmacokinetic profiles between these two&#xD;
      pegylated IFNs. Currently, IFN-based therapy to treatment HCV infection should be initiated&#xD;
      in dialysis stages, because the use of IFN in RT patients harbors high risks of acute graft&#xD;
      rejection,(22,23) and have low response rates under the concomitant use of immunosuppressive&#xD;
      agents.(24,25) Ribavirin, which has been used in combination with IFN to treat chronic&#xD;
      hepatitis C in the general patients and achieve a higher SVR rate than IFN monotherapy, is&#xD;
      considered contraindicated in dialysis patients with chronic hepatitis C due to the risk of&#xD;
      severe hemolytic anemia. However, some pilot studies evaluating combined conventional IFN&#xD;
      alfa plus low dose ribavirin (170-300 mg/day) showed SVR rates of 17%-66% after 24-48 weeks&#xD;
      of treatment.(26-28) In addition, a recent study including 6 patients with combination of&#xD;
      pegylated IFN alfa plus low dose ribavirin also showed a SVR rate of 50%.(29) Although&#xD;
      dialysis patients have a higher SVR rate to conventional IFN or pegylated IFN monotherapy&#xD;
      than patients with normal renal function for HCV therapy. More than half of these patients&#xD;
      are relapsers or non-responders to IFN monotherapy. Retreatment of HCV-patients with normal&#xD;
      renal function by combined pegylated IFN alfa plus ribavirin who fail to response to IFN&#xD;
      monotherapy has achieved a SVR rate of 28%.(30) Based on the long-term favorable outcome in&#xD;
      dialysis patients who eradicate HCV, the aim of the study is to evaluate the efficacy and&#xD;
      safety of retreatment by pegylated IFN alfa-2a plus low dose ribavirin in dialysis patients&#xD;
      who fail to achieve HCV eradication by conventional or pegylated IFN alfa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Number of participants with sustained virologic response (SVR): number of patients with undetectable HCV RNA 6 months off therapy by real-time PCR test (Cobas TaqMan HCV Test v2.0, Roche Diagnostics GmbH, Mannheim, Germany, limit of detection &lt; 25 IU/mL)&#xD;
Number of participants who droppoed out of the study prematurely due to adverse events (AEs): number of patients who prematurely withdrew from the study due to any adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Histologic Response(HR)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Number of participants with histologic response (HR): number of patients who had improvement of as least 2 scores at the end of follow-up liver biopsy compared to baseline liver biopsy by Ishak scoring system (the sum of Ishak necroinflammation score (0-18) and Ishak fibrosis score (0-6); the higher the total scores, the severer the histologic changes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Pegylated IFN + RBV for HCV genotype 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks for HCV genotype 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated IFN + RBV for HCV genotype 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks for HCV genotype 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a and ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks</description>
    <arm_group_label>Pegylated IFN + RBV for HCV genotype 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a and ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks</description>
    <arm_group_label>Pegylated IFN + RBV for HCV genotype 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-responders or relapsers of dialysis patients to conventional interferon or&#xD;
             pegylated interferon monotherapy&#xD;
&#xD;
          -  Age 18~65 years old&#xD;
&#xD;
          -  Creatinine clearance (Ccr) &lt; 10 ml/min/1.73 m2&#xD;
&#xD;
          -  Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months&#xD;
&#xD;
          -  Detectable serum quantitative HCV-RNA (Cobas Taqman HCV Monitor v2.0, Roche&#xD;
             Diagnostics) with dynamic range 25- 391000000 IU/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe anemia (hemoglobin &lt; 10 g/dL) or hemoglobinopathy&#xD;
&#xD;
          -  Neutropenia (neutrophil count, &lt;1,500/mm3)&#xD;
&#xD;
          -  Thrombocytopenia (platelet &lt;90,000/ mm3)&#xD;
&#xD;
          -  Co-infection with HBV or HIV&#xD;
&#xD;
          -  Chronic alcohol abuse (daily consumption &gt; 20 g/day)&#xD;
&#xD;
          -  Autoimmune liver disease&#xD;
&#xD;
          -  Decompensated liver disease (Child classification B or C)&#xD;
&#xD;
          -  Neoplastic disease&#xD;
&#xD;
          -  An organ transplant&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,&#xD;
             psychiatric diseases, neurological diseases, diabetes mellitus&#xD;
&#xD;
          -  Evidence of drug abuse&#xD;
&#xD;
          -  Unwilling to have contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, National Taiwan Universitys Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002 Jul;36(1):3-10. doi: 10.1053/jhep.2002.34613.</citation>
    <PMID>12085342</PMID>
  </reference>
  <reference>
    <citation>Kao JH, Huang CH, Chen W, Tsai TJ, Lee SH, Hung KY, Chen DS. GB virus C infection in hemodialysis patients: molecular evidence for nosocomial transmission. J Infect Dis. 1999 Jul;180(1):191-4. doi: 10.1086/314850.</citation>
    <PMID>10353878</PMID>
  </reference>
  <reference>
    <citation>Hou CH, Chen WY, Kao JH, Chen DS, Yang Y, Chen JJ, Lee SH, Wu DJ, Yang SC. Intrafamilial transmission of hepatitis C virus in hemodialysis patients. J Med Virol. 1995 Apr;45(4):381-5. doi: 10.1002/jmv.1890450405.</citation>
    <PMID>7545208</PMID>
  </reference>
  <reference>
    <citation>Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999 Jul 10;354(9173):93-9. doi: 10.1016/s0140-6736(99)06154-1.</citation>
    <PMID>10408483</PMID>
  </reference>
  <reference>
    <citation>Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000 Oct;11(10):1896-1902. doi: 10.1681/ASN.V11101896.</citation>
    <PMID>11004221</PMID>
  </reference>
  <reference>
    <citation>Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998 Oct;32(4):629-34. doi: 10.1016/s0272-6386(98)70027-7.</citation>
    <PMID>9774125</PMID>
  </reference>
  <reference>
    <citation>Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998 May;53(5):1374-81. doi: 10.1046/j.1523-1755.1998.00883.x.</citation>
    <PMID>9573555</PMID>
  </reference>
  <reference>
    <citation>Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999 Jan;29(1):257-63. doi: 10.1002/hep.510290123.</citation>
    <PMID>9862875</PMID>
  </reference>
  <reference>
    <citation>Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. 1998 Aug 27;66(4):471-6. doi: 10.1097/00007890-199808270-00010.</citation>
    <PMID>9734490</PMID>
  </reference>
  <reference>
    <citation>Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998 Mar 15;65(5):667-70. doi: 10.1097/00007890-199803150-00011.</citation>
    <PMID>9521201</PMID>
  </reference>
  <reference>
    <citation>Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis. 2000 Mar;181(3):852-8. doi: 10.1086/315355.</citation>
    <PMID>10720504</PMID>
  </reference>
  <reference>
    <citation>Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Brechot C, Pol S. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant. 2002 Jan;17(1):129-33. doi: 10.1093/ndt/17.1.129.</citation>
    <PMID>11773476</PMID>
  </reference>
  <reference>
    <citation>Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1071-81. doi: 10.1046/j.1365-2036.2003.01780.x.</citation>
    <PMID>14653826</PMID>
  </reference>
  <reference>
    <citation>Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003 Jul;98(7):1610-5. doi: 10.1111/j.1572-0241.2003.07526.x.</citation>
    <PMID>12873587</PMID>
  </reference>
  <reference>
    <citation>Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, Isik IO. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006 Mar;21(3):575-80. doi: 10.1111/j.1440-1746.2005.04008.x.</citation>
    <PMID>16638102</PMID>
  </reference>
  <reference>
    <citation>Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, Vernic C. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol. 2006 Jul 14;12(26):4191-4. doi: 10.3748/wjg.v12.i26.4191.</citation>
    <PMID>16830372</PMID>
  </reference>
  <reference>
    <citation>Chan TM, Ho SK, Tang CS, Tse KC, Lam MF, Lai KN, Yung S. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton). 2007 Feb;12(1):11-7. doi: 10.1111/j.1440-1797.2006.00662.x.</citation>
    <PMID>17295655</PMID>
  </reference>
  <reference>
    <citation>Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006 Feb;21(2):437-43. doi: 10.1093/ndt/gfi231. Epub 2005 Oct 18.</citation>
    <PMID>16234288</PMID>
  </reference>
  <reference>
    <citation>Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther. 2004 Jul 1;20(1):123-4; author reply 124. doi: 10.1111/j.1365-2036.2004.01954.x. No abstract available.</citation>
    <PMID>15225179</PMID>
  </reference>
  <reference>
    <citation>Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol. 2005 Mar;63(3):232-5. doi: 10.5414/cnp63232.</citation>
    <PMID>15786827</PMID>
  </reference>
  <reference>
    <citation>Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferon-alpha-induced acute renal allograft rejection. Transplantation. 1995 Apr 15;59(7):1068-70. doi: 10.1097/00007890-199504150-00030. No abstract available.</citation>
    <PMID>7709447</PMID>
  </reference>
  <reference>
    <citation>Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc. 2004 Apr;36(3):760-2. doi: 10.1016/j.transproceed.2004.03.041.</citation>
    <PMID>15110654</PMID>
  </reference>
  <reference>
    <citation>Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects. Transplant Proc. 1995 Feb;27(1):948-50. No abstract available.</citation>
    <PMID>7879242</PMID>
  </reference>
  <reference>
    <citation>Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol. 2001 Apr;96(4):1170-7. doi: 10.1111/j.1572-0241.2001.03697.x.</citation>
    <PMID>11316166</PMID>
  </reference>
  <reference>
    <citation>Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004 Jul-Aug;36(6):1831-4. doi: 10.1016/j.transproceed.2004.07.025.</citation>
    <PMID>15350490</PMID>
  </reference>
  <reference>
    <citation>Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study. J Viral Hepat. 2001 Jul;8(4):287-92. doi: 10.1046/j.1365-2893.2001.00300.x.</citation>
    <PMID>11454181</PMID>
  </reference>
  <reference>
    <citation>Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2001 Aug;16(8):1729. doi: 10.1093/ndt/16.8.1729. No abstract available.</citation>
    <PMID>11477195</PMID>
  </reference>
  <reference>
    <citation>Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006 May;13(5):316-21. doi: 10.1111/j.1365-2893.2005.00680.x.</citation>
    <PMID>16637862</PMID>
  </reference>
  <reference>
    <citation>Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947. doi: 10.1053/j.gastro.2004.01.014.</citation>
    <PMID>15057741</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>June 23, 2007</study_first_submitted>
  <study_first_submitted_qc>June 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>December 21, 2008</results_first_submitted>
  <results_first_submitted_qc>October 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 13, 2009</results_first_posted>
  <last_update_submitted>October 7, 2009</last_update_submitted>
  <last_update_submitted_qc>October 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Chen-Hua Liu</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>interferon</keyword>
  <keyword>ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: June 2006- June 2007 Location: 5 academic centers</recruitment_details>
      <pre_assignment_details>Wash out period: 6 months after last interferon intervention</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pegylated Interferon and Ribavirin for 48 Weeks (Genotype 1)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Pegylated Interferon and Ribavirin for 24 Weeks (Genotype 2)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegylated Interferon and Ribavirin for 48 Weeks (Genotype 1)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Pegylated Interferon and Ribavirin for 24 Weeks (Genotype 2)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="8"/>
                    <measurement group_id="B2" value="44" spread="12"/>
                    <measurement group_id="B3" value="47" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs)</title>
        <description>Number of participants with sustained virologic response (SVR): number of patients with undetectable HCV RNA 6 months off therapy by real-time PCR test (Cobas TaqMan HCV Test v2.0, Roche Diagnostics GmbH, Mannheim, Germany, limit of detection &lt; 25 IU/mL)&#xD;
Number of participants who droppoed out of the study prematurely due to adverse events (AEs): number of patients who prematurely withdrew from the study due to any adverse events</description>
        <time_frame>1.5 year</time_frame>
        <population>Outcome measures:intention-to-treat (ITT) analysis Imputation technique: last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Interferon and Ribavirin for 48 Weeks (Genotype 1)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pegylated Interferon and Ribavirin for 24 Weeks (Genotype 2)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs)</title>
          <description>Number of participants with sustained virologic response (SVR): number of patients with undetectable HCV RNA 6 months off therapy by real-time PCR test (Cobas TaqMan HCV Test v2.0, Roche Diagnostics GmbH, Mannheim, Germany, limit of detection &lt; 25 IU/mL)&#xD;
Number of participants who droppoed out of the study prematurely due to adverse events (AEs): number of patients who prematurely withdrew from the study due to any adverse events</description>
          <population>Outcome measures:intention-to-treat (ITT) analysis Imputation technique: last observation carried forward</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sustained virologic response (SVR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drop-out</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Histologic Response(HR)</title>
        <description>Number of participants with histologic response (HR): number of patients who had improvement of as least 2 scores at the end of follow-up liver biopsy compared to baseline liver biopsy by Ishak scoring system (the sum of Ishak necroinflammation score (0-18) and Ishak fibrosis score (0-6); the higher the total scores, the severer the histologic changes)</description>
        <time_frame>1.5 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Interferon and Ribavirin for 48 Weeks (Genotype 1)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pegylated Interferon and Ribavirin for 24 Weeks (Genotype 2)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Histologic Response(HR)</title>
          <description>Number of participants with histologic response (HR): number of patients who had improvement of as least 2 scores at the end of follow-up liver biopsy compared to baseline liver biopsy by Ishak scoring system (the sum of Ishak necroinflammation score (0-18) and Ishak fibrosis score (0-6); the higher the total scores, the severer the histologic changes)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>Constitutional symptoms and abnormal laboratory tests</desc>
      <group_list>
        <group group_id="E1">
          <title>Pegylated Interferon and Ribavirin for 48 Weeks (Genotype 1)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Pegylated Interferon and Ribavirin for 24 Weeks (Genotype 2)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal stuffiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Body weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rigor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chen-Hua Liu</name_or_title>
      <organization>National Taiwan University Hospital</organization>
      <phone>886223123456 ext 63572</phone>
      <email>jacque_liu@mail2000.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

